NT-3-secreting human umbilical cord mesenchymal stromal cell transplantation for the treatment of acute spinal cord injury in rats

Transplantation of umbilical cord–derived mesenchymal stem cells as a novel strategy to protect the central nervous system: technical aspects, preclinical studies, and clinical perspectives

“…This has been achieved using viral and nonviral methods, mainly with MSCs isolated from adult tissues. Significant transfection efficiency has also been obtained with MSCs isolated from human UCB and Wharton's jelly (83)(84)(85). The combination of properties of MSCs makes them of particular interest for cell-based therapies in central nervous system injury and disease.…”

“…For example, to track grafted cells in a transplantation experiment, hUC-MSCs were transfected with the green fluorescent protein (GFP) reporter gene, and GFP-expressing cells sorted using fluorescence-assisted cell sorting (85). Later, the same authors used recombinant adenoviruses containing the NT-3 gene to genetically modify the GFP-hUC-MSCs and make them overexpress NT-3.…”

Modified Bone Marrow Stromal Cells Therapy for Central Nervous System Disorders

“…Stem cells are a kind of cells characterized of species diversity, selfreplication and renewal ability, high proliferation potential and multiple differentiation potential [1][2][3][4]. Compared with other types of stem cell transplantation, treatment using Bone Marrow Stromal Cells (BMSCs) has more advantage, which has rich resources, easy to access, multiple potential, ethical limits, subculture amplification etc.…”

“…Combination stem cells with biomaterials is another direction in the research of the central nervous system injury [25,26]. Some research had constructed biological composite materials to control the releasing of neurotrophic factors and stem cells transplantation.…”

Genetic modification of mesenchymal stem cells in spinal cord injury repair strategies

“…Sprague-Dawley (SD) rats in a NT-3-human umbilical cord MSCs (HUMSCs) group had significantly improved locomotor function recovery and more than the control group in a rat model for clipped SCI (19). The NT-3-HUMSCs group achieved better functional recovery, more intensive 5-HT fibers, a larger volume of spared myelination, and a smaller area of cystic cavity than the HUMSCs group at the end of 12 weeks after SCI.…”